U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H19ClN2
Molecular Weight 310.821
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Desloratadine

SMILES

ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C4CCNCC4)=C1

InChI

InChIKey=JAUOIFJMECXRGI-UHFFFAOYSA-N
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2

HIDE SMILES / InChI
Molecular Formula C19H19ClN2
Molecular Weight 310.821
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).

CNS Activity

Approval Year

2001
187
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 0.87 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
CLARINEX

Approved Use

Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Launch Date

2001
Palliative
Approved
8583
CLARINEX

Approved Use

Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Launch Date

2001
Palliative
Approved
8583
CLARINEX

Approved Use

Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
56.9 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
27 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
84.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.25 mg 1 times / day steady, oral
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf
unhealthy, 2-11 years
Health Status: unhealthy
Age Group: 2-11 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf
Disc. AE: Somnolence, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Somnolence (1 patient)
Abdominal pain (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf
45 mg 1 times / day multiple, oral
Highest studied dose
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 1 patient
Disc. AE
1.25 mg 1 times / day steady, oral
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf
unhealthy, 2-11 years
Health Status: unhealthy
Age Group: 2-11 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf
Somnolence 1 patient
Disc. AE
1.25 mg 1 times / day steady, oral
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf
unhealthy, 2-11 years
Health Status: unhealthy
Age Group: 2-11 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946
inhibitor
2438
substrate
1388

inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2C8
1057

CYP2C19
2057

CYP2B6
926

CYP3A4/5
296

UGT1A1
246

UGT1A3
89

UGT1A4
98

UGT1A6
136

UGT1A9
148

UGT2B7
197

UGT2B10
31

UGT2B15
84

UGT2B17
31

UGT1A7
23

UGT1A8
37

UGT1A10
37

UGT2B4
23

P-gp
1741
CYP1A2
1197

CYP2B6
776

CYP1A1
389

CYP2C19
1119

UGT2B10
131

P-gp
2052
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no
CYP2C19
2141
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
UGT1A1
303
 no
UGT1A3
99
 no
UGT1A4
100
 no
UGT1A6
171
 no
UGT1A7
25
 no
UGT1A8
49
 no
UGT1A9
155
 no
UGT2B15
84
 no
UGT2B7
210
 no
P-gp
1932
 not significant [IC50 43 uM]
UGT2B10
33
 strong [Ki 1.3 uM]
CYP2B6
1160
 weak [Inhibition 10 uM]
CYP2D6
2546
 weak [Inhibition 10 uM]
CYP3A4/5
357
 weak [Inhibition 10 uM]
UGT1A10
46
 weak [Inhibition 10 uM]
UGT2B17
33
 weak [Inhibition 10 uM]
UGT2B4
23
 weak [Inhibition 10 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A1
389
 likely
CYP1A2
1197
 likely
CYP2B6
776
 likely
CYP2C19
1119
 likely
no (pharmacogenomic study)
Comment: pharmacogenotype 2C19 does not correlate with systemic exposure
Page: 19.0
CYP2D6
1388
 likely
no (pharmacogenomic study)
Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation
Page: 10.0
CYP3A4
1946
 likely
weak (co-administration study)
Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively.
Page: 10.0
UGT2B10
131
 yes
P-gp
2052
 yes
weak (co-administration study)
Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively.
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:291342
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:291342
ChemicalBook
CB3462564
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3462564
eMolecules
877481
https://www.emolecules.com/cgi-bin/more?vid=877481
MolPort
MolPort-000-883-875
https://www.molport.com/shop/molecule-link/MolPort-000-883-875
Selleck Chemicals
desloratadine
http://www.selleckchem.com/products/desloratadine.html
ZINC
ZINC000000001261
http://zinc15.docking.org/substances/ZINC000000001261
PubMed

PubMed

TitleDatePubMed
Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine.
2004-04
High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs.
2004-03-10
Gateways to clinical trials.
2004-02-28
Inhibition of cold urticaria by desloratadine.
2004-01
Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research.
2004-01
Gateways to clinical trials.
2003-12
Interactions of olopatadine and selected antihistamines with model and natural membranes.
2003-12
Desloratadine for allergic rhinitis.
2003-11-15
[Modern antihistaminics against allergic rhinitis. Better breathing without side effects].
2003-10-30
Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma.
2003-10-25
Loratadine, desloratadine and pregnancy: don't use, risk of hypospadias.
2003-10
A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis.
2003-10
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment.
2003-10
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.
2003-10
Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin.
2003-10
Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine.
2003-08-13
Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men.
2003-08
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.
2003-08
Studies on performance and sleepiness with the H1-antihistamine, desloratadine.
2003-08
Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma.
2003-07-25
Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
2003-07
Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects.
2003-07
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma.
2003-07
[Safety of new antihistamines].
2003-06
[Clinical aspects of anti-inflammatory action of antihistamines].
2003-06
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis.
2003-06
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.
2003-06
Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure.
2003-06
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis].
2003-05-25
First do no harm: managing antihistamine impairment in patients with allergic rhinitis.
2003-05
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.
2003-04
Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
2003-04
Gateways to clinical trials. March 2003.
2003-03
Double-stranded RNA viruses in a mycocinogenic strain of Cystofilobasidium infirmominiatum.
2003-03
Decongestant effects of antihistamines: a class effect?
2003-03
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis.
2003-03
P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.
2003-03
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma.
2003-02
Desloratadine: a nonsedating antihistamine.
2003-02
The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study.
2003-01-06
Severe hepatotoxicity after application of desloratadine and fluconazole.
2003
Desloratadine: an update of its efficacy in the management of allergic disorders.
2003
Chronic urticaria: a role for newer immunomodulatory drugs?
2003
Comparative pharmacology of H1 antihistamines: clinical relevance.
2002-12-16
Treatment of allergic rhinitis.
2002-12-16
The new antihistamines--desloratadine and levocetirizine: a review.
2002-12
[The place of new antihistamines in allergy management. Apropos of desloratadine].
2002-12
Desloratidine for the treatment of chronic urticaria.
2002-10
Second-generation antihistamines in asthma therapy: is there a protective effect?
2002
Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion.
2002
Patents

Patents

05714609
8
06075025
4
06492381
4
JP4739217B2
51

Sample Use Guides

In Vivo Use Guide
Adults and Adolescents 12 Years of Age and Over: take 5 mg tablet once daily. Children 6 to Years of Age: take 2.5 mg tablet once daily. Children 12 Months to 5 Years of Age: take 1.25 mg tablet once daily. Children 6 to 11 Months of Age: 1 mg tablet once daily.
Route of Administration: Oral
In Vitro Use Guide
Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.
Substance Class Chemical
Created
by admin
on Wed Apr 02 06:53:05 GMT 2025
Edited
by admin
on Wed Apr 02 06:53:05 GMT 2025
Record UNII
FVF865388R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLARINEX-D COMPONENT DESLORATADINE
Preferred Name English
Desloratadine
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
8-Chloro-5,6-dihydro-11-(piperidin-4-ylidene)-11H-benzo[5,6]cyclohepta[1,2-b]pyridine)
Systematic Name English
DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, URTICARIA)
Brand Name English
DESLORATADINE RATIOPHARM
Brand Name English
DENOSIN
Brand Name English
desloratadine [INN]
Common Name English
5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-
Systematic Name English
DASSELTA
Brand Name English
NSC-759824
Code English
DESLORATADINE [MART.]
Common Name English
LORATADINE RELATED COMPOUND A [USP IMPURITY]
Common Name English
NEOCLARITYN
Brand Name English
DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)
Brand Name English
DESLORATADINE [MI]
Common Name English
DESLORATADINE [VANDF]
Common Name English
DESLORATADINE [USP-RS]
Common Name English
RUPATADINE FUMARATE IMPURITY B [EP IMPURITY]
Common Name English
DESLORATADINE [USP MONOGRAPH]
Common Name English
CLARINEX
Brand Name English
DESCARBOETHOXYLORATADINE
Common Name English
DESLORATADINE ACTAVIS
Brand Name English
DESLORATADINE TEVA (AUTHORIZED: RHINITIS, URTICARIA)
Brand Name English
DESLORATADINE [ORANGE BOOK]
Common Name English
OPULIS
Brand Name English
SCH-34117
Code English
AZOMYR
Brand Name English
ALLEX
Brand Name English
Desloratadine [WHO-DD]
Common Name English
DESLORATADINE TEVA
Brand Name English
LORATADINE IMPURITY D [EP IMPURITY]
Common Name English
AERIUS
Brand Name English
DESLORATADINE [JAN]
Common Name English
LORATADINE RELATED COMPOUND A [USP-RS]
Common Name English
DESLORATADINE [EMA EPAR]
Common Name English
DESLORATADINE [EP MONOGRAPH]
Common Name English
DESLORATADINE [USAN]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS DESLORATADINE TEVA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
LIVERTOX NBK548831
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
WHO-VATC QR06AX27
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
EMA ASSESSMENT REPORTS OPULIS (WITHDRAWN: RHINITIS, URTICARIA)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
NCI_THESAURUS C29578
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
NDF-RT N0000175587
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
EMA ASSESSMENT REPORTS ALLEX(WITHDRAWN: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
EMA ASSESSMENT REPORTS DASSELTA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
EMA ASSESSMENT REPORTS DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
EMA ASSESSMENT REPORTS DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
EMA ASSESSMENT REPORTS AZOMYR (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
WHO-ATC R06AX27
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
EMA ASSESSMENT REPORTS AERINAZE (AUTHORIZED: RHINITIS)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
EMA ASSESSMENT REPORTS AERIUS(AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
EMA ASSESSMENT REPORTS NEOCLARITYN (AUTHORIZED: RHINITIS, URTICARIA)
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
NDF-RT N0000000190
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL1172
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
DRUG BANK
DB00967
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
RS_ITEM_NUM
1370280
Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025
ALTERNATIVE
MESH
C121345
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
CHEBI
291342
Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025
PRIMARY
INN
7817
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
RXCUI
275635
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY RxNorm
SMS_ID
100000089395
Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025
PRIMARY
EPA CompTox
DTXSID1044196
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
LACTMED
Desloratadine
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
NCI_THESAURUS
C47474
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
NSC
759824
Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025
PRIMARY
PUBCHEM
124087
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
USAN
KK-46
Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025
PRIMARY
DRUG CENTRAL
814
Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025
PRIMARY
FDA UNII
FVF865388R
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
DAILYMED
FVF865388R
Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025
PRIMARY
WIKIPEDIA
Desloratadine
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
RS_ITEM_NUM
1173042
Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025
PRIMARY
IUPHAR
7157
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
MERCK INDEX
m4193
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY Merck Index
EVMPD
SUB01596MIG
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
CAS
100643-71-8
Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A3
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B10
TRANSPORTER -> INHIBITOR
Ki
CYTOCHROME P450 2C9
METABOLIC ENZYME -> NON-INHIBITOR
CYTOCHROME P450 2C8
METABOLIC ENZYME -> NON-INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
HISTAMINE H1 RECEPTOR
TARGET -> INHIBITOR
Desloratadine bound to membranes expressing the recombinant human histamine H1 receptor in Chinese hamster ovary cells (CHO-H1).
Kd
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CYTOCHROME P450 2C19
METABOLIC ENZYME -> NON-INHIBITOR
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B10
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
WEAK
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
Structure of DESLORATADINE HEMISULFATE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2B6
METABOLIC ENZYME -> INHIBITOR
WEAK
HISTAMINE H1 RECEPTOR
TARGET -> INHIBITOR
Kd
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
METABOLIC ENZYME -> SUBSTRATE
Structure of DESLORATADINE CITRATE DISODIUM
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
OCT-2
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 2D6
METABOLIC ENZYME -> INHIBITOR
WEAK
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B15
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 1A2
METABOLIC ENZYME -> NON-INHIBITOR
Related Record Type Details
Structure of 6-HYDROXYDESLORATADINE
METABOLITE -> PARENT
IN VITRO
Structure of 5-HYDROXYDESLORATADINE
METABOLITE -> PARENT
IN VITRO
Structure of LORATADINE
PARENT -> METABOLITE ACTIVE
MAJOR
Structure of 3-HYDROXYDESLORATADINE O-GLUCURONIDE
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
Structure of DECHLORO DESLORATADINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-nitroso-desloratadine
IMPURITY -> PARENT
Structure of 5H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE, 8-CHLORO-6,11-DIHYDRO-11-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LORATADINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DEHYDRO DESLORATADINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FLUORODESLORATADINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LORATADINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LORATADINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 1-PIPERIDINECARBOXALDEHYDE, 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YLIDENE)-
IMPURITY -> PARENT
Structure of 8-BROMO-DESLORATADINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of RUPATADINE FUMARATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of Desloratadine
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC DOSE

ONCE DAILY

ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966